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ABSTRACT The interleukin-17 (IL-17) family of cy-
tokines plays important roles in innate immune de-
fenses against bacterial and fungal pathogens. While
much is known about IL-17A, much less information is
available about the IL-17F isoform. Here, we investi-
gated gene expression and release of IL-17F and its
regulation by the complement system. IL-17F was pro-
duced in mouse peritoneal elicited macrophages after
TLR4 activation by LPS, peaking after 12 h. This effect
was completely dependent on the presence of the
adaptor protein MyD88. The copresence of the com-
plement activation product, C5a (EC5010 nM), ampli-
fied IL-17F production via the receptor C5aR. In vitro
signaling studies indicated that LPS or C5a, or the
combination, caused phosphorylation of Akt occurring
at threonine 308 but not at serine 473. Treatment of
macrophages with pharmacologic inhibitors of PI3K-
Akt greatly reduced production of IL-17F as well as
mRNA for IL-17F. In endotoxemia, C5a levels peaked
at 6 h, while IL-17F levels peaked between 6–12 h. Full
in vivo production of IL-17F during endotoxemia re-
quired C5a. A similar result was found in the cecal
ligation and puncture sepsis model. These data suggest
that maximal production of IL-17F requires comple-
ment activation and presence of C5a.—Bosmann, M.,
Patel, V. R., Russkamp, N. F., Pache, F., Zetoune, F. S.,
Sarma, J. V., Ward, P. A. MyD88-dependent production
of IL-17F is modulated by the anaphylatoxin C5a via
the Akt signaling pathway. FASEB J. 25, 4222–4232
(2011). www.fasebj.org
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The complement system evolved early during the
development of life. It can be found in all vertebrates
and all major invertebrate deuterostome groups but is
not found in protostome genomes such as Caenorhabdi-
tis elegans or Drosophila melanogaster (1). The function of
this arm of innate immune defenses is not only to
provide rapid clearance of extracellular pathogens but
also to provide immune surveillance and homeostasis
(2, 3). Activation of the classic, alternative, and MB-
lectin pathways all lead to formation of the C3-conver-
tase followed by the C5-convertase. The terminal com-
plement components C5–C9 interact to form the
membrane-attack complex (C5b-9), while C3b op-
sonizes pathogens directly to facilitate phagocytosis.
The cleavage products C3a and the more potent C5a
act as powerful anaphylatoxins to recruit phagocytic
cells to the site of complement activation and further
promote inflammation (4). C5a is rapidly converted to
C5adesArg by the serum enzyme carboxypeptidase N,
resulting in a half-life for C5a in the circulation of 5
min (5). C5a and the less active C5adesArg both bind
with high affinity to the two receptors C5aR (CD88)
and C5L2 (GPR77), which are expressed abundantly
on myeloid and to a lesser extent on nonmyeloid cells
(6). The C5aR receptor is a traditional G-protein-
coupled receptor that, when ligated to C5a, results in
responses from neutrophils and macrophages that
leads to rapid Ca2 currents, activation of MAPK sig-
naling, chemotaxis, respiratory burst, and release of
toxic granules (7, 8). C5a and the C5a receptors are
critically involved in the pathogenesis and outcome of
acute inflammatory diseases, namely acute lung injury/
ARDS and sepsis (9–11). Antibody blockade of C5a is
protective in experimental sepsis (12). Similarly, block-
ade or genetic absence of C5aR or C5L2 improve
survival during polymicrobial sepsis induced by cecal
ligation and puncture (CLP; ref. 13). Furthermore, C5a
directly acts on cardiomyocytes to induce mediator
release and is involved in the development of cardiac
dysfunction during sepsis (14, 15).
The interleukin-17 (IL-17) family of cytokines in-
cludes IL-17A-E and IL-17F, of which the founding
member, IL-17A, is the best described isoform (16, 17).
IL-17F and IL-17A share 50–55% sequence homology,
with their genes located close together on chromosome
1 (mouse) and chromosome 6 (human). Both isoforms
can exist in disulfide-linked homo- or heterodimers
(18). IL-17F binds to the IL-17RA/IL-17RC receptors
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(19). The cellular sources of IL-17F are not only CD4
Th17 cells but a wide range of cells, including CD8 T
cells, NKT cells, and LTi-like cells (16, 20). Even colon
epithelial cells have been reported to express mRNA
for IL-17F (21). Target cells of IL-17F are primarily
nonmyeloid cells, such as fibroblast, keratinocytes, sy-
noviocytes, and endothelial cells. From these cells,
IL-17F induces mediator production of TNF-, IL-1,
IL-6, G-CSF, and CXC chemokines (16, 22, 23). In
addition, IL-17F enhances gene expression of antimi-
crobial peptides (24). Taken together, these effects
amplify protective immune responses against microbial
infections. Recent studies have suggested that IL-17F is
required for clearance of Klebsiella pneumonia infection
of the lung and Staphylococcus aureus from the mucoepi-
thelium (21, 25). In humans, genetic defects for IL-17F
or IL-17RA have been associated with chronic mucocu-
taneous candidiasis disease, further underscoring the
role of IL-17F in mucosal immune defense (26). On the
other hand, IL-17 family members have also been
implicated in the pathogenesis of autoimmune disease.
We have recently reported that IL-17A is detrimental
during experimental sepsis (27). Here, we report on
the regulation of the expression of IL-17F by the
complement component, C5a, and the signaling mech-
anisms involved.
MATERIALS AND METHODS
Animals
All procedures were performed in accordance with the U.S.
National Institutes of Health guidelines and the University
Committee on Use and Care of Animals (UCUCA), University
of Michigan. Male mice of the strains C57BL/6J and
MyD88/ (B6.129P2(SJL)-Myd88tm1.1Defr/J) were purchased
from the Jackson Laboratories (Bar Harbor, ME, USA) at an
age of 8–10 wk. Mice of the strain C5aR/ (on a C57BL/6J
background) were bred and genotyped at the University of
Michigan. All animals were housed under specific pathogen-
free conditions.
Isolation and incubation of macrophages
Mice were injected i.p. with 1.5 ml thioglycollate (2.4% w/v;
Becton Dickinson, Franklin Lakes, NJ, USA), and peritoneal
elicited macrophages (PEMs) were harvested by peritoneal
lavage with HBSS 4 d later. After centrifugation (650 g, 5 min,
4°C), cells were resuspended in medium [RPMI 1640 with 25
mM HEPES (Life Technologies, Inc., Carlsbad, CA, USA),
100 U/ml penicillin-streptomycin (Life Technologies), and
0.1% BSA (Sigma-Aldrich, St. Louis, MO, USA)]. Purity of
macrophage preparations was confirmed by flow cytometry;
typically, 85–90% of cells stained positive for F4/80. Cells
were plated at a density of 2  106 cells/ml in polystyrene
culture plates and incubated at 37°C, 5% CO2. At the end of
all experiments, supernatants were cleared of nonadherent
cells by centrifugation and stored at 80°C until further
analysis.
In vivo experiments
Endotoxemia
Mice were injected i.p. with LPS (Escherichia coli 0111:B4,
Sigma-Aldrich) in a dose of 10 mg/kg body weight. Body
weight of each individual animal was measured directly
before injection. Blood was collected from the retro-orbital
sinus under deep anesthesia using EDTA (5–10 mM) as an
anticoagulant. Plasma was separated by centrifugation (2000
g, 10 min, 4°C) and stored at 80°C until further analysis.
Cecal ligation and puncture (CLP)
The CLP procedure was performed as described previously,
with the surgeon blinded to the studied groups of mice (28,
29). Briefly, mice were anesthetized by i.p. injection of
ketamine (100 mg/kg body weight; Fort Dodge Animal
Health, Fort Dodge, IA, USA) and xylazine (8 mg/kg body
weight, Akorn Inc., Lake Forest, IL, USA). After a small
midline abdominal incision (1 cm), the peritoneum was
opened, and the cecum was exteriorized and ligated with 4-0
braided silk (Henry Schein Inc., Melville, NY, USA) directly
below the ileocecal valve. The cecum was punctured through
and through with an 18-gauge needle, and a small amount of
feces was extruded to assure patency. After wound closure,
the animals received 1 ml 0.9% sterile NaCl s.c. for fluid
resuscitation. This form of CLP (“high grade”) usually causes
severe sepsis and results in lethality of most animals within
4–5 d. At the end of experiments, the plasma was processed
as described above, and spleens were snap-frozen in liquid
nitrogen and stored at 80°C until further analysis.
Measurement of mediator concentrations by ELISA
For detection of mouse IL-17F, an ELISA kit (R&D Systems,
Minneapolis, MN, USA) with no cross-reactivity for the other
isoforms of IL-17 (IL-17A–IL-17E) was used. Plasma and
supernatants were diluted in PBS with 1% BSA to fit in the
range of standards. ELISAs were performed according to the
instructions of the manufacturer. The ELISA for mouse C5a
was performed under optimized conditions with antibodies
and recombinant C5a standard purchased separately from
BD Biosciences (San Jose, CA, USA).
Isolation of mRNA and real time PCR
Total RNA from macrophages was obtained by the Trizol
method. The cDNA was generated with TaqMan Reverse
Transcription Reagents (Applied Biosystems, Foster City, CA,
USA) in a GeneAmp PCR System 9700 (Applied Biosystems;
25°C for 10 min, 48°C for 30 min, 95°C for 5 min). Amplifi-
cation was performed with SYBR Green Mastermix in the
7500 real-time PCR System (Applied Biosystems; 50°C for 2
min; 95°C for 10 min; 40 cycles: 95°C for 10 s, 60°C for 60 s,
72°C for 10 s). Results were analyzed by the 2Ct relative
quantification method and normalized to GAPDH. Primers
for mouse IL-17F (QT00144347) were purchased from Qia-
gen (Valencia, CA, USA). Forward and reverse primer se-
quences for mouse GAPDH were5-TACCCCCAATGTGTC-
CGTCGTG-3 and 5-CCTTCAGTGGGCCCTCAGATGC-3,
respectively (Invivogen, San Diego, CA, USA).
Flow cytometry
For intracellular cytokine staining, cells were incubated with
Brefeldin A. Samples were processed using the Cytofix/
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Cytoperm Plus Fixation/Permeabilization Kit (BD Biosci-
ences), following the instructions of the manufacturer, and
blockade of Fc receptors (BD Fc Block). For flow cytometry of
phosphoproteins, cells were fixed with fixation buffer (BD
Cytofix; BD Biosciences) and permeabilized with the harsh
alcohol method (Perm Buffer III, BD Biosciences). A mini-
mum of 50,000 events was acquired on a BD LSR II flow
cytometer (BD Biosciences); dot-plot images depict 10,000
events. All antibodies used were anti-mouse together with
matched fluorochrome labeled isotype controls. From BD
Pharmingen (San Diego, CA, USA): AF488 anti-Akt (pS473;
clone M89–61), PE anti-Akt (pT308; clone J1-223.371). From
eBioscience (San Diego, CA, USA): APC F4/80 (clone BM8),
eFluor450 F4/80 (clone BM8), PE-Cy7 CD11b (clone M1/
70), PE Mac-3 (clone M3/84), AF488 IL-17F (clone
eBio18F10). From BioLegend (San Diego, CA, USA): PE
C5aR (clone 20/70).
Antibodies and reagents
Toll-like receptor (TLR) agonists were obtained from Invivogen:
TLR2 (zymosan from Saccharomyces cerevisiae), TLR3 [poly(I:C)],
TLR5 (flagellin from Bacillus subtilis), TLR9 (type A CpG oligo-
nucleotide ODN1518 and ODN 1585 control). LPS was from E.
coli (0111:B4, Sigma-Aldrich), LY294002 and Wortmannin were
from Invivogen. Recombinant mouse C5a was from R&D sys-
tems (endotoxin level 1.0 EU/g protein). Normal goat
serum was from Equitech-Bio Inc. (Kerrville, TX, USA).
Neutralizing polyclonal goat anti-C5a antiserum was pro-
duced as described before and characterized to effectively
block rat and mouse C5a (30, 31). Briefly, the carboxyl-
terminal peptide of the rat C5a sequence (CTIADKIRKESH
HKGMLLGR; amino acid residues 58–77) was synthesized;
the peptide was coupled to keyhole limpet hemocyanin by the
glutaraldehyde method and used for the immunization of
goats and production of sera.
Statistical analysis
GraphPad Prism 5.03 software (GraphPad, San Diego, CA,
USA) was used for figure preparation and statistical analysis.
All values are expressed as means 	 se. Data sets were
analyzed by 1-way ANOVA or Student’s t test. We considered
differences significant at values of P  0.05. In vitro experi-
ments were performed independently at least 2 or 3 times,
and representative experiments are shown. For in vivo exper-
iments, the numbers of animals per group were as indicated
in the figure legends (n3).
RESULTS
Release of IL-17F from PEMs after TLR4-activation
by LPS
To study the production and release of IL-17F, we used
cell cultures of PEMs from C57BL/6J wild-type mice.
Macrophages were incubated with agonists for the
different TLRs. After 10 h the cell culture supernatants
were analyzed for levels of IL-17F by ELISA (Fig. 1A). In
Figure 1. Production and release of
IL-17F by macrophages in response
to LPS. A) PEMs from C57BL/6J
(wild-type) mice were stimulated
with agonists for different TLRs (all
1 g/ml). IL-17F was detected in
the supernatants after 10 h by
ELISA. Control (Ctrl) macrophages
were incubated with medium alone.
B) Dose-response studies of IL-17F
release from macrophages after in-
cubation with different concentra-
tions of LPS (10 ng/ml to 1 g/ml)
for 10 h. C) Time course of IL-17F
release from macrophages after LPS
(1 g/ml). D) Time course of
mRNA levels for IL-17F in macro-
phages after LPS (1g/ml) as detected by RT-PCR. E) Flow cytometry with intracellular staining for IL-17F or isotype control (top
left) or costaining for IL-17F and macrophage surface markers (Mac-3, CD11b, and F4/80). Macrophages were stimulated with
LPS (1 g/ml) for 6 h in the presence of Brefeldin A before staining. FI, fluorescence intensity. *P  0.05 vs. Ctrl; Student’s t
test.
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supernatant fluids from macrophages incubated with
medium alone (control), IL-17F was not detectable
(detection limit 
20 pg/ml). Macrophages stimulated
with LPS (1 g/ml) for activation of the TLR4 receptor
robustly released IL-17F after 10 h. Using agonists for
the pattern-recognition-receptors TLR2, TLR3, TLR5,
and TLR9, no appearance of IL-17F in supernatants was
observed. Next, we performed dose-response studies
using different concentrations of LPS and detection of
IL-17F levels after 10 h (Fig. 1B). LPS induced IL-17F
from macrophages with an EC50 of 25–50 ng/ml.
Concentrations of LPS above 100 ng/ml resulted in
robust production of IL-17F. For all further experi-
ments, LPS at a concentration of 1 g/ml was used to
induce maximal IL-17F release, unless otherwise indi-
cated. LPS at 1 g/ml (E. coli, 0111:B4) did not exert
cytotoxic effects on PEMs for the incubation period
employed in these experiments (data not shown). A
time course of IL-17F release after TLR4 activation by
LPS is shown in Fig. 1C. IL-17F was not detectable at the
3 h time point, but was present after 6 h. Additional
release of IL-17F was observed at the 10–12 h time
points. Levels did not further increase with longer
incubation times, such as 24 h (data not shown). We
also analyzed the abundance of mRNA for IL-17F in
PEMs in response to LPS (Fig. 1D). In untreated
macrophages, IL-17F mRNA was barely detectable, but
increased 25-fold at 3 h and 400-fold at 6 h when
macrophages were stimulated with LPS. Levels of IL-
17F mRNA declined at 12 h. Accordingly, the increases
of IL-17F on the mRNA level preceded appearance of
IL-17F protein in the supernatant fluids (Fig. 1C, D).
Finally, we investigated the presence of intracellular
IL-17F in macrophages by flow cytometry (Fig. 1E).
LPS-stimulated peritoneal cells stained with higher
fluorescence intensity using an anti-IL-17F antibody as
compared to the isotype control (Fig. 1E, top left).
Intracellular staining for IL-17F correlated with the
presence of macrophage surface markers. Percentages
of double-positive cell populations were 56.8% for
IL-17FMac-3, 67.7% for IL-17CD11b, and 50.6%
for IL-17FF4/80, respectively. Notably, the markers
Mac-3 and CD11b have also been described to be
present on cells of the myeloid lineage other than
macrophages. CD11b can be expressed on neutrophils
and Mac-3 is known to also be expressed to some extent
on dendritic cells and endothelial cells. Therefore, we
used the surface marker F4/80 for all further experi-
ments as a marker for murine macrophages.
MyD88 is essential for expression and release of
IL-17F after TLR4 activation by LPS
The myeloid differentiation primary response gene 88
(MYD88) is critical for the production of inflammatory
cytokines in response to a variety of microbial products.
On the molecular level, MyD88 serves as universal adaptor
protein to all TLRs (except TLR3) and the IL-1R1 recep-
tor. Thus, the inflammatory response is dependent on
MyD88, although especially for TLR4 additional MyD88-
independent signaling pathways exist. For example, in the
genetic absence of MyD88, antigen-presenting cells can
still respond to LPS by activation of NFB with delayed
kinetics and release cytokines such as IL-27p28 at reduced
levels (32, 33). To investigate the role of MyD88 in the
TLR4-induced production of IL-17F, we incubated PEMs
from wild-type mice and MyD88/ mice with LPS. Cell
culture fluids were harvested 10 h later (Fig. 2A). Wild-
type macrophages released IL-17F robustly after LPS
incubation, whereas cells with the genetic absence of
MyD88 showed no release of detectable IL-17F. The
concentration of LPS used in these experiments was 1
g/ml, which is a dose 
20 times higher than the EC50
concentration of LPS for wild-type macrophages to pro-
duce IL-17F (Fig. 1B). The data on the absence of IL-17F
protein release from LPS-stimulated MyD88/ macro-
phages was supported by similar findings, when mRNA
levels for IL-17F were measured (Fig. 2B). For these
experiments macrophages were incubated for 6 h, since
in the previous experiments (Fig. 1D) the highest levels
for IL-17F mRNA after LPS were found at this time point.
In unstimulated macrophages from wild-type mice, IL-17F
mRNA was again barely detectable but became abun-
dantly present with addition of LPS. However, in LPS-
stimulated macrophages from MyD88/ mice, IL-17F
mRNA remained undetectable after 40 cycles of real time
PCR (Fig. 2B, right).
C5a modulates IL-17F production through
engagement of the C5aR receptor
Cells of the myeloid lineage, including macrophages,
are known to abundantly express the C5a receptor,
C5aR (CD88). We performed flow cytometry staining of
macrophages for C5aR together with staining for the
F4/80 marker and intracellular IL-17F (Fig. 3A). We
gated on F4/80, so that the histogram shown as Fig. 3A
only depicts cells that were found positive for F4/80
compared to staining with the isotype control. Thus,
flow cytometry analysis revealed that the vast majority of
Figure 2. MyD88 is essential for production and release of
IL-17F after LPS. A) PEMs from C57BL/6J (wild-type) mice
and MyD88/ mice were stimulated in parallel with LPS or
left as untreated controls. IL-17F levels in the cell culture
supernatants were detected by ELISA after 10 h. B) RT-PCR
for IL-17F mRNA in wild-type macrophages and MyD88/
macrophages after LPS, 6 h. LPS was used at 1 g/ml in all
experiments. *P  0.05 vs. Ctrl; #P  0.05 vs. Myd88/;
Student’s t test.
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F4/80 macrophages were not only producing IL-17F
after LPS but also abundantly expressed the C5aR
receptor on the cell surface (F4/80C5aRIL-17F
cells). Next, we sought to test the hypothesis that C5a
may alter the release of IL-17F from F4/80C5aRIL-
17F macrophages, since the expression of C5aR sug-
gests that these cells would be responsive to C5a.
Macrophages were left as untreated controls or incu-
bated with LPS alone or with the combination of LPS
plus recombinant mouse C5a (100 nM). After 10 h, cell
culture fluids were collected, and levels of IL-17F were
quantified by ELISA (Fig. 3B). Indeed, the addition of
C5a resulted in higher levels of IL-17F released from
macrophages, which on average were 
200% in the
copresence of 100 nM C5a as compared to LPS alone.
The effect of C5a in the copresence of LPS was dose-
dependent, with an EC50 of 
10 nM for C5a (Fig. 3C).
When cells from C5aR/ mice were compared to
wild-type cells, C5a could not enhance IL-17F levels
(Fig. 3D). This suggests that ligation of C5a to the C5aR
receptor is required to the initiate intracellular signal
transduction events for the modulation of IL-17F re-
lease by C5a.
C5a mediates site specific phosphorylation of Akt at
amino acid residue threonine 308
We have previously reported that C5a can activate Akt
(also known as protein kinase B) in human and rat
neutrophils (34, 35). Binding of phosphatidylinositol
(3,4,5)-triphosphate (PIP3) results in translocation of
Akt to the plasma membrane and activation of Akt to
phospho-Akt by upstream kinases. Specifically, Akt can
be phosphorylated at threonine 308 (T308) by the
kinase PDPK1 and/or phosphorylation at serine 473
(S473) by the kinase mTORC2. We employed flow
cytometry using antibodies specific for the phosphory-
lation sites T308 and S473 to investigate the effects of
C5a and LPS on the Akt signaling pathway in F4/80
macrophages. A time course of the effects of C5a on the
phosphorylation status of Akt at T308 is shown in
Fig. 4A. Baseline phosphorylation (0 min) was 2.8%
and increased with duration of C5a incubation. After 20
min, the number of phospho-Akt(T308)F4/80 cells
was 14.0%, which represented a 5-fold increase. The
gate used for data analysis and staining with isotype
control compared to the phospho-Akt(T308) antibody
is shown in Supplemental Fig. S1. A different pattern
was observed when phosphorylation of Akt at S473 was
studied in response to C5a (Fig. 4B). In fact, no
significant increase in the number of phospho-
Akt(S473)F4/80 macrophages (1.5% at 0 min vs.
2.9% at 20 min) was seen in the presence of C5a (100
nM). Similar results were obtained when phosphoryla-
tion of Akt after addition of LPS (1 g/ml) was studied
(Fig. 4C). The number of phospho-Akt(T308)F4/80
macrophages shifted from 1.5% at 0 min to 35.2% at 20
Figure 3. Complement component C5a regulates the release of IL-17F via the
C5aR receptor. A) Macrophages were stimulated with LPS for 6 h in the presence
of Brefeldin A. Cells were then triple-stained for F4/80, IL-17F, and C5aR and
analyzed by flow cytometry. Events shown are gated for F4/80 positivity. B) Release
of IL-17F from macrophages after incubation with LPS or LPS plus recombinant
C5a (100 nM). Ctrl denotes untreated cells, 10 h, ELISA. C) Dose-response studies
of modulation of IL-17F release by C5a using the indicated concentrations of C5a.
D) Macrophages from wild-type and C5aR/ mice were stimulated with LPS or
LPS plus C5a for 10 h. For expressing the relative release of IL-17F (%), the
amount of IL-17F with LPS alone was set to 100% for each cell type. LPS was used
at 1 g/ml in all experiments. *P 0.05 vs. Ctrl; #P 0.05 vs. LPS; Student’s t test.
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min after incubation with LPS (Fig. 4C, left panel).
However, LPS had very limited ability to phosphorylate
Akt at S473 in F4/80 macrophages (1.3 vs. 3.4%, Fig.
4C, right panel).
Synergistic activation of the Akt signaling pathway by
C5a and LPS and dependency on MyD88
To further investigate the role of Akt for transmission
of the intracellular signals after binding of C5a and LPS
to their receptors, we studied the capability of C5a to
further enhance the phosphorylation of Akt in the
copresence of LPS. According to the results presented
above, we focused our further studies on the phosphor-
ylation site T308 of Akt. First, we report the results
obtained with PEMs from C57BL/6J wild-type mice:
when such F4/80 macrophages were incubated for
different durations of time with LPS alone, the number
of phospho-Akt(T308)F4/80 double-positive cells in-
creased from 2.3 (0 min) to 30.6% (20 min; Fig. 5A, top
panel). When macrophages were stimulated with the
combination of LPS and recombinant C5a, the phos-
phorylation of Akt at site T308 increased more rapidly
and to higher absolute cell numbers (Fig. 5A, bottom
panel). After 5 min with LPS plus C5a, the number of
phospho-Akt(T308)F4/80 double-positive cells was
13.3.% as compared to 3.6% with LPS alone. At the
20-min time point, LPS plus C5a resulted in 48.2%
phospho-Akt(T308)F4/80 macrophages, whereas
30.6% double-positive cells were counted when LPS was
used alone in this experiment.
In addition to macrophages from wild-type mice, we
also studied the time course for Akt phosphorylation after
LPS and LPS plus C5a in macrophages from MyD88/
mice. The experiment and all data in Fig. 5 for wild-type
and MyD88/ macrophages were performed side by side
on the same day. One representative of two independent
experiments is shown. Not surprisingly, the extent of
phosphorylation of Akt in response to LPS was markedly
abrogated in macrophages with the genetic absence of
MyD88 (Fig. 5B, top panel). After 20 min with LPS (1
g/ml), the number of phospho-Akt(T308)F4/80
double-positive macrophages from MyD88/ mice was
only 9.7% as compared to 30.6% in macrophages from
wild-type mice (Fig. 5A, top panel). On combined incu-
bation with LPS and C5a, macrophages from MyD88/
Figure 4. C5a and LPS activate Akt by phosphorylation at the
amino acid residue threonine 308 but not serine 473. A) Macro-
phages were incubated for the indicated time periods with recom-
binant C5a. Phosphorylation status was preserved by formalde-
hyde fixation, and cells were stained for phospho-Akt (T308) plus
F4/80 and analyzed by flow cytometry. B) Staining for phospho-
Akt (S473) and F4/80 after incubation with C5a as described
above. C) Macrophages were incubated with LPS for 20 min and
analyzed for phosphorylation of Akt at amino acid residue T308
(left panel) or amino acid residue S473 (right panel).
Figure 5. Synergistic activation of Akt by C5a and LPS is reduced in the absence of MyD88. A) PEMs from wild-type mice were
incubated for the indicated time periods with either LPS alone or the combination of LPS plus C5a. Cells were stained for F4/80
and phospho-Akt (T308) and analyzed by flow cytometry. B) Macrophages from MyD88/ mice were incubated with LPS or
LPS plus C5a and stained for F4/80 and phospho-Akt (T308). LPS, 1 g/ml; C5a, 100 nM.
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mice responded with significant but nevertheless less
phosphorylation of Akt as compared to wild-type macro-
phages after 20 min (26.6 vs. 48.2%). Incubation of
MyD88/ macrophages with C5a alone resulted in sim-
ilar levels of Akt phosphorylation at T308 as compared to
wild-type macrophages after 20 min (data not shown).
Pharmacologic blockade of the phosphoinositide
3-kinase (PI3K)-Akt signaling pathway abrogates
IL-17F production
To address the question of whether the activation of
Akt by LPS and C5a is the relevant signal transduction
pathway subsequently mediating IL-17F gene expres-
sion and release, we studied how IL-17F is affected
when Akt inhibition is performed. The pharmacologic
small-molecule inhibitors Wortmannin and LY294002
were used for these experiments. Wortmannin irrevers-
ibly inactivates PI3K by a covalent binding reaction,
which thereby prevents further downstream activation
of Akt. PEMs were incubated with different doses of
Wortmannin (5 M–40 nM) for 10 h in the presence of
LPS, and IL-17F was detected by ELISA (Fig. 6A).
Compared to IL-17F levels after LPS alone, the release
of IL-17F from LPS-activated macrophages was pro-
foundly suppressed by Wortmannin at all concentra-
tions employed. In contrast to Wortmannin, LY294002
is a reversible inhibitor of PI3K and displays somewhat
less potency. However, IL-17F release from LPS-stimu-
lated macrophages was effectively antagonized even
with low concentrations of LY294002 (Fig. 6B). Specif-
ically, with the lowest concentration of LY294002 (1
M) LPS-induced IL-17F levels were reduced by 38%.
Further support of our hypothesis that the PI3K-Akt
pathway is essential for gene expression of IL-17F after
LPS was obtained by RT-PCR. The mRNA levels for
IL-17F were substantially lower in macrophages after
activation by LPS, when the macrophages had been
pretreated with Wortmannin (Fig. 6C). Similar suppres-
sion of IL-17F mRNA was evident when LY294002 was
used to inhibit the PI3K-Akt pathway (Fig. 6D). When
macrophages were incubated with Wortmannin or
LY294002 alone, no effects on IL-17F protein or mRNA
was observed (data not shown). In addition, no cyto-
toxic effects were observed with either Wortmannin or
LY294002 under the conditions employed as evaluated
by light microscopy at the end of experiments.
C5a regulates the appearance of IL-17F during acute
systemic immune responses
According to the data presented above, we have dem-
onstrated that the release of IL-17F is regulated by the
anaphylatoxin C5a, when recombinant C5a is added to
cell cultures of peritoneal macrophages activated by
LPS. To further collect evidence that the complement
Figure 6. Pharmacologic blockade of the PI3K-Akt signaling pathway inhibits
the release of IL-17F. A) Macrophages from wild-type mice were incubated for
10 h with LPS alone or LPS plus different doses of the PI3K inhibitor
Wortmannin (5 M to 40 nM). Cell culture upernatants were analyzed for
presence of IL-17F by ELISA. Ctrl denotes untreated macrophages. B) Macro-
phages were incubated with LPS alone or LPS plus different doses of the PI3K
inhibitor LY294002 (25–1 M) and IL-17F was detected after 10 h. C) IL-17F
mRNA expression profiles analyzed by RT-PCR from macrophages after incu-
bation with LPS or the combination of LPS and Wortmannin, 10 h. D) IL-17F
mRNA levels from macrophages after LPS or LPS plus LY294002 in different
concentrations, 10 h. All data shown were acquired using peritoneal macro-
phages from C57BL/6J wild-type mice. *P  0.05 vs. LPS; Student’s t test.
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system through C5a may regulate IL-17F-dependent
immune functions, we sought to study the effects of C5a
on IL-17F during acute systemic inflammation in vivo.
We used a model of lethal endotoxemia, where a high
dose of LPS (E. coli, 10 mg/kg body weight) is admin-
istered i.p. In this experimental setting, mice begin to
develop signs of acute illness (lethargy, hypothermia,
periorbital exudates, piloerection) within a few hours,
and lethality is 60–80%, with most of the deaths usually
occurring between 24–48 h after LPS injection (data
not shown). Using this model of endotoxemia, plasma
was collected at several time points after challenge with
LPS but before mice succumbed to cardiovascular
shock. A time-course study of C5a appearance in
plasma from endotoxemic wild-type mice revealed that
C5a levels reached the maximum 6 h after injection of
LPS (Fig. 7A). Levels of C5a were 5- to 6-fold higher as
compared to levels detected in the plasma of mice
injected with vehicle alone (sham). We cannot rule out
the possibility that the C5a levels detected in sham-
treated mice represent cross-reactivity of the ELISA
assay with C5 rather than true presence of C5a. Next,
we investigated the kinetics of circulating IL-17F. As
shown in Fig. 7B, levels of IL-17F in plasma peaked at
6–12 h in the endotoxemia model. Thereby, the ap-
pearance of C5a preceded the release of IL-17F in
plasma. To test the hypothesis that levels of IL-17F in
endotoxemia are influenced by the presence of C5a, we
used a blocking polyclonal goat anti-C5a antiserum to
neutralize C5a. When anti-C5a serum was given 2 h
before the administration of LPS, the levels of IL-17F
were reduced by 
50% as compared to animals that
received a normal control serum followed by LPS (Fig.
7C). Finally, we expanded our investigation on polymi-
crobial sepsis after cecal ligation and puncture (CLP).
This model of disease has been considered by many to
be the gold standard for research on experimental
sepsis and similar to the endotoxemia model results in
a systemic inflammatory response. In mice 10 h after
CLP, we found IL-17F to be present at levels of 
150
pg/ml (Fig. 7D), meaning IL-17F release was lower as
compared to the findings in the endotoxemia model.
The CLP procedure was performed in a design causing
severe sepsis and high mortality (high-grade CLP). In
control mice undergoing anesthesia and sham surgery,
IL-17F in plasma was not detectable. Similar to the
findings after endotoxemia, the neutralization of C5a
with administration of a blocking anti-C5a antiserum
2 h before CLP resulted in a significant reduction of
circulating IL-17F after 12 h (Fig. 7E). In summary, the
release of IL-17F appeared to be regulated by C5a in
the two studied experimental models (endotoxemia
and CLP), which are known to be characterized by a
Figure 7. C5a modulates the release of
IL-17F during acute inflammatory responses
in vivo. A) Appearance of C5a in plasma
during lethal endotoxemia (LPS, 10 mg/kg
body weight, i.p., n4/group), ELISA.
Plasma was collected at the indicated time
points. B) Plasma levels of IL-17F during
endotoxemia. Wild-type mice were injected
with LPS (10 mg/kg body weight, i.p.) and
IL-17F was detected by ELISA (n3–6/
group). C) Plasma levels of IL-17F during
endotoxemia with blockade of C5a by a neu-
tralizing anti-C5a antiserum. Mice were in-
jected i.p. with 0.5 ml of either normal con-
trol serum or anti-C5a serum 2 h before
injection of LPS (10 mg/kg body weight, i.p.). Plasma was analyzed for appearance of IL-17F after 12 h. D) Levels of IL-17F
in plasma during polymicrobial sepsis induced by cecal ligation and puncture (CLP), 12 h. Mice underwent either sham
surgery (n3) or high-grade CLP (n4). E) Levels of IL-17F in plasma after CLP with blockade of C5a. Neutralization of C5a
was achieved by anti-C5a antiserum and compared to normal control serum as described above for endotoxemia; n  6 for
each group. *P  0.05; Student’s t test.
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severe systemic inflammatory response, including acti-
vation of the complement system.
DISCUSSION
Our data indicate that the expression of the IL-17F
isoform is regulated by the complement activation
product C5a. Production and release of IL-17F from
F4/80 macrophages in response to LPS was com-
pletely dependent on the TLR4-associated adaptor pro-
tein MyD88. In the presence of C5a, the levels of IL-17F
increased synergistically with the effects of LPS. Con-
versely, with blockade of C5a during acute systemic
inflammation using the models of endotoxemia and
CLP, the amounts of IL-17F detectable in plasma were
reduced. The intracellular signaling mechanisms un-
derlying the observation that C5a and LPS interact for
the gene expression of IL-17F appear to be linked to
Akt. C5a and LPS both induced rapid activation of Akt.
Interestingly, phosphorylation of Akt in F4/80 macro-
phages was mostly heavily targeted for the amino acid
residue threonine 308 with very limited phosphoryla-
tion at amino acid residue serine 473. The extent of Akt
phosphorylation was higher when LPS and C5a were
used in combination as compared to LPS or C5a alone,
which is consistent with the finding that LPS plus C5a
resulted in higher levels of IL-17F released from mac-
rophages. Blockade of the PI3K-Akt signaling pathways
with the specific inhibitors Wortmannin and LY294002
profoundly incapacitated macrophages for producing
IL-17F protein and mRNA. Furthermore, the activation
of Akt was dependent of MyD88. The proposed molec-
ular mechanisms according to the data presented in
this report are shown in Fig. 8.
There are accumulating reports in the literature that
IL-17 isoforms can be produced by cells of the innate
immune system in addition to IL-17 derived from Th17
cells (20, 27, 36–38). Cells of the myeloid lineage, such
as neutrophils, have been suggested to be a source of
IL-17 after LPS instillation into the lung or after kidney
ischemia-reperfusion injury (36, 39). Substantial levels
of IL-17A were still released in the genetic absence of
 T cells after CLP, whereas  T cells contributed to
IL-17A production in this model (27). Levels of IL-17A
after CLP were reduced but not completely absent in
Rag-1/ mice after CLP (29). Interestingly, in endo-
toxic shock the genetic absence of  T cells,  T cells,
or CD4 cells did not result in diminished plasma
IL-17A levels after 12 h, whereas depletion of F4/80
macrophages did (unpublished results.) Furthermore,
IL-17A can be produced by peritoneal macrophages
and is suppressed by IL-10 in these cells (40). Genetic
absence of IL-10 was accompanied by elevated expres-
sion of RORt in macrophages together with increased
IL-17A release on LPS stimulation (40). LPS-stimulated
wild-type macrophages that produced lower levels of
IL-17A failed to show evidence for expression of
RORt. In a murine model of asthma, the house dust
mite induced production of IL-17A was attenuated in
MyD88 deficient mice (41). In addition, macrophages
produce IL-17A in response to chitin in a manner that
was dependent on both TLR2 and MyD88 (42). How-
ever, most studies so far have focused on IL-17A,
whereas much less is known about the production and
regulation of IL17F from innate immune cells. The
production of cytokines in response to LPS is not
necessarily entirely dependent on MyD88 since TLR4
can signal using both the MyD88 and TRIF pathways.
For example, IL-18 can be cleaved from proIL-18 in
Kupffer cells from MyD88 deficient mice and IL-27p28
levels after LPS are only reduced by 50–70% in macro-
phages from such animals (33, 43). However, according
to our findings, MyD88 is essential for the release of
IL-17F in response to LPS, since we observed complete
absence of IL-17F generation with genetic deficiency of
MyD88.
There is growing evidence that the complement
system can positively or negatively regulate the re-
sponses of components of the innate and adaptive
immune system. Specifically, the anaphylatoxin C5a is
being generated in large quantities after formation of
the C5-convertase. C5a does not only attract and acti-
vate neutrophils and other phagocytic cells to the site of
complement activation but also interferes with the
extent of mediator production by these cells, via signal
transduction molecules such as Akt. For example, C5a
has differential effects on TNF- release from rat
neutrophils and alveolar macrophages (35). Further-
more, C5a enhances the expression of IL-8 from LPS-
activated human neutrophils and regulates IL-6 from
rat neutrophils after CLP (44, 45). Furthermore, C5a
has been demonstrated to interfere with the release of
Th1 cytokines such as IL-12 and IL-23 from LPS-
stimulated murine macrophages and human mono-
Figure 8. Proposed mechanisms for the regulation of the
release of IL-17F based on the data presented herein.
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cytes (46, 47). Lymphocytes, namely, T cells are also
responsive to C5a, since T cells express the C5aR
receptor and are chemoattracted to C5a (48). Clonal
expansion of T cells is also enhanced by C5a through
limitation of lymphocyte apoptosis and C5a enhances
T-cell activation (49, 50). Several reports have recently
suggested a role of the complement system and C5a to
interfere with Th17 cell responses and expression of
IL-17A (51–54). For example, in a model of severe
airway hyperresponsiveness, IL-17A apparently was re-
ciprocally regulated by the anaphylatoxins C5a and
C3a, when mouse strains deficient of the complement
factor C5, C5aR, or C3aR were studied (52). Dendritic
cells from C5aR-deficient mice have been found to
promote the induction of Th17 cells after activation of
TLR2 or with ovalbumin (54). However, the exact
influence of complement activation on directing and
orchestration of Th1, Th2, and Th17 cell responses
may vary depending on the disease model studied.
Notably, the time course and magnitude of C5a gener-
ation as well as the responsiveness to C5a after binding
to the C5aR receptor may differ depending if chronic
or acute inflammatory diseases are studied. To our
knowledge, the data presented here is the first detailed
report specifically addressing the effects of C5a on the
IL-17F isoform and characterizing some of the intracel-
lular signaling events involved. It suggests that the
extent of IL-17F-dependent immune response can be
modulated and fine-tuned by the complement system.
In our future work, we plan to further address the
question on how the complement system regulates
innate and adaptive immune functions and how the
understanding of these mechanisms can eventually be
employed for new therapeutic strategies for human
disease.
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